Titan Spine has appointed Chad Kolean as chief financial officer. In his role, Kolean will oversee Titan’s Finance Team and work to support the company’s growth following the launch of its NanoLock surface technology.
Prior to joining Titan, Chad Kolean served as chief financial officer at Cellectar Biosciences, a life sciences company. Previously he was chief financial officer at Pioneer Surgical Technologies. Kolean is a certified public accountant and earned his Bachelor of Arts degree in Business Administration from Hope College (Holland, USA).
Kolean comments, “I am thrilled to join the team at Titan Spine, particularly at such an exciting time for the company. We are well-positioned for continued financial growth that capitalises on a strong first half of 2017.”
NanoLock surface technology is roughened to the nano-level
Titan Spine offers a full line of Endoskeleton titanium implants that feature its proprietary NanoLock surface technology. NanoLock was launched in the USA in October 2016 following US Food and Drug clearance in late 2014.
The surface technology consists of a unique combination of roughened topographies at the macro-, micro-, and nano-levels. This combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process. By promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins, downregulating inflammatory factors, the technology is intended to create potential for a faster and more robust fusion.
An in-depth look at the NanoLock technology and its competitors can be found in our recent surface technology feature.
All Endoskeleton devices are covered by the company’s risk share warranty.
